3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase NA
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
9
Plasma cell
1
Other hematologic neoplasm
1
Dermatologic
1
Conditions
Multiple Myeloma
725
Neoplasms, Plasma Cell
135
Lymphoma, Non-Hodgkin
118
Lymphoma
111
Recurrence
103
Leukemia, Lymphocytic, Chronic, B-Cell
99
Precursor Cell Lymphoblastic Leukemia-Lymphoma
93
Leukemia, Myeloid, Acute
92
Hodgkin Disease
92
Lymphoma, Large B-Cell, Diffuse
83
Leukemia
75
Lymphoma, Mantle-Cell
71
Myelodysplastic Syndromes
70
Lymphoma, Follicular
69
Burkitt Lymphoma
60
Lymphoma, B-Cell, Marginal Zone
59
Neoplasms
54
Lymphoma, Large-Cell, Immunoblastic
54
Waldenstrom Macroglobulinemia
42
Myeloproliferative Disorders
39
Leukemia, Myelomonocytic, Chronic
39
Leukemia, Myeloid, Chronic-Phase
39
Primary Myelofibrosis
38
Immunoglobulin Light-chain Amyloidosis
38
Hematologic Neoplasms
38
Lymphoma, T-Cell, Cutaneous
36
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
35
Lymphoma, Large-Cell, Anaplastic
34
Leukemia, Myeloid, Accelerated Phase
34
Blast Crisis
33
Interventions
ficlatuzumab
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphatic Diseases
×
Plasma cell
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled